Investor Presentation First Nine Months of 2022
38
Investor presentation First nine months of 2022
GLP-1 and SGLT-2i have been driving the value growth of the
global diabetes care market
Estimated global number of patients
Estimated global diabetes value market
CAGR: +4%
$
CAGR: +5%
192 million
218 million
USD 47 billion
USD 55 billion
2018
Insulin
2021
GLP-1
SGLT-2i
2018
DPP-4i
2021
Traditional OADs
•
.
Novo NordiskⓇ
Diabetes market dynamics
Continued strong growth momentum in
GLP-1 and SGLT-2i segments, but from a
larger base
DPP-4i segment to have first patent
expiries on key products within the
coming two years
Flat insulin volume growth and continued
insulin pricing pressure
Note: GLP-1+basal insulin combination sales are included in insulin; Traditional OADS include metformin, SU and TZDS. CAGR: Compound annual growth rates. OAD: Oral anti-diabetes
Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADS as of December 2018 and 2021View entire presentation